We are live on ! Find out more
GNMX

Aevi Genomic Medicine Inc
GNMX

Delisted

GNMX was delisted on the 3rd of February, 2020.

Back to rankings

43 hedge funds and large institutions have $45.8M invested in Aevi Genomic Medicine Inc in 2015 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 14 increasing their positions, 11 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 4

71% more capital invested

Capital invested by funds: $26.8M → $45.8M (+$19M)

53% more call options, than puts

Call options by funds: $164K | Put options by funds: $107K

27% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 11

13% more funds holding

Funds holding: 38 → 43 (+5)

Holders
43
Holders Change
+5
Holders Change %
+13.16%
% of All Funds
1.15%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
9
Increased
14
Reduced
11
Closed
4
Calls
$164K
Puts
$107K
Net Calls
+$57K
Net Calls Change
+$57K

Top Buyers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
+$943K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$537K
3
CS
Credit Suisse
Switzerland
+$294K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$287K
5
BIT
BlackRock Institutional Trust
California
+$256K

Top Sellers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
-$377K
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$171K
3
WA
WFG Advisors
Texas
-$101K
4
Jennison Associates
Jennison Associates
New York
-$93.5K
5
Deutsche Bank
Deutsche Bank
Germany
-$87K
Name Holding Trade Value Shares
Change 		Change in
Stake
VanEck Associates
26
VanEck Associates
New York
$136K -$9.1K -1,206 -7%
SIM
27
Spark Investment Management
New York
$124K +$30.9K +4,100 +36%
BCM
28
BlueCrest Capital Management
Jersey
$120K +$112K +14,901 New
CDH
29
Charles D. Hyman
$105K – – –
Bank of New York Mellon
30
Bank of New York Mellon
New York
$105K +$98.2K +13,015 New
UBS Group
31
UBS Group
Switzerland
$100K +$92.1K +12,205 +6,103%
Morgan Stanley
32
Morgan Stanley
New York
$63K +$20.4K +2,700 +52%
ICM
33
Ionic Capital Management
New York
$60K +$56.6K +7,500 New
BA
34
BlackRock Advisors
Delaware
$31K – – –
BIM
35
BlackRock Investment Management
Delaware
$23K +$950 +126 +5%
Wells Fargo
36
Wells Fargo
California
$15K -$39.6K -5,250 -74%
Citigroup
37
Citigroup
New York
$14K -$1.21K -160 -9%
LTFS
38
Ladenburg Thalmann Financial Services
Florida
$12K -$38.8K -5,150 -78%
BKA
39
Brick & Kyle Associates
Pennsylvania
$8K – – –
Creative Planning
40
Creative Planning
Kansas
$8K – – –
TWA
41
TCI Wealth Advisors
Arizona
$8K – – –
TDC
42
Thompson Davis & Co
Virginia
$2K +$1.89K +250 New
TRCT
43
Tower Research Capital (TRC)
New York
$1K -$1.21K -160 -63%
WA
44
WFG Advisors
Texas
– -$101K -20,000 Closed
Deutsche Bank
45
Deutsche Bank
Germany
– -$87K -17,197 Closed
BRWA
46
B. Riley Wealth Advisors
Florida
– -$10 -2,000 Closed
Simplex Trading
47
Simplex Trading
Illinois
– -$1.25K -165 Closed
1
2

GNMX Hedge Fund Activity: Q1 2015 in Review

43 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q1 2015, worth a combined $45.8M — up 71% from $26.8M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new GNMX positions and 4 closed out — a net gain of 5 holders — while 14 added to existing stakes and 11 trimmed.

The largest buyer was Perceptive Advisors, adding an estimated $943K. The largest seller was Sphera Funds Management, cutting an estimated $377K.

  • 43 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q1 2015, up from 38 in Q4 2014.
  • Funds reported $45.8M of Aevi Genomic Medicine Inc stock for Q1 2015, up 71% quarter-over-quarter.
  • 9 funds opened new Aevi Genomic Medicine Inc positions in Q1 2015 and 4 closed out, a net change of +5 holders.
  • The largest Aevi Genomic Medicine Inc buyer in Q1 2015 was Perceptive Advisors, an estimated $943K added.
  • The largest Aevi Genomic Medicine Inc seller in Q1 2015 was Sphera Funds Management, an estimated $377K sold.

Based on aggregated 13F filings for Q1 2015.